Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer. (Q46426888)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24142531%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

title

Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24142531%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24142531%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

Dan Su

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24142531%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Li-Jie Wang

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24142531%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Wei-Wei Shi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24142531%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Yan-Yan Long

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24142531%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Juan Li

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24142531%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Li Bai

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24142531%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

publication date

19 October 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24142531%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24142531%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24142531%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24142531%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

2313-2318

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24142531%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s13277-013-1306-x

28 February 2020

exact match

0 references

cites work

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1306-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1306-X

Surgery for pancreatic cancer: recent controversies and current practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1306-X

A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1306-X

Genomics and pharmacogenomics of pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1306-X

Management strategies in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1306-X

Epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1306-X

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1306-X

Targeting EGFR in pancreatic cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1306-X

Systemic treatment of advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1306-X

Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1306-X

Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1306-X

Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1306-X

Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1306-X

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1306-X

Meta-analysis of phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1306-X

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1306-X

Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1306-X

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1306-X

Cetuximab: still an option in the treatment of pancreatic cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1306-X

Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1306-X

21 January 2018

1 reference

12 December 2020

Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer

1 reference

12 December 2020

Efficacy of gemcitabine combined with erlotinib in patients with advanced pancreatic cancer

1 reference

12 December 2020

Novel agents in early phase clinical studies on refractory pancreatic cancer.

1 reference

12 December 2020

Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.

1 reference

12 December 2020

Erlotinib in the treatment of advanced pancreatic cancer

1 reference

12 December 2020

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

12 December 2020

10.1007/S13277-013-1306-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24142531%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference